NASDAQ · SXTPW

60 Degrees Pharmaceuticals, Inc.

$0.03 +$0.00 (+13.75%) 1D Market open

Key Metrics

$9.82K
Market cap
P/E · TTM
$1.00M
Revenue · TTM
−$7.58M
Net income
EPS · TTM $-23.62
Dividend yield
Free cash flow −$8.16M
Beta · 1Y 1.13
EBITDA · TTM −$7.53M
Gross margin 20.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    A material event was filed (Form 8-K).

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 10
    From its Mar 16 high, the share price fell 77%.

    Peak close $0.10 on Mar 16; trough close $0.02 on Jul 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -77%
  • Mar 16
    The stock moved +119.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 16
  • Mar 11
    The stock moved +84.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value−$4.41M
Shares outstanding
52-wk range$0.02 – $0.16
Avg volume · 20D11.1K
Net cash $4.42M
Book value / share$15.05
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About 60 Degrees Pharmaceuticals, Inc.
IPO dateJul 12, 2023
Employees3

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.01
P/FCF
EV/EBITDA
EV/Sales-4.39
Graham №

Profitability

Gross 20.9%
Operating -755.1%
Net -754.8%
FCF -812.8%
ROE / ROIC -171.0% · —

Financial Health

Current ratio3.34
Quick ratio2.85
Debt / equity0.03
Debt / EBITDA -0.02
Net cash $4.42M
Working capital$4.38M

Cash Flow · TTM

Operating CF −$7.99M
Capex −$167.20K
Free cash flow −$8.16M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-13.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings